Thoracic spinal cord myelopathy from complex arachnoid web formation/exacerbation after palliative radiation therapy for spinal metastasis: illustrative case Authors: Raven D. Spencer, Clementina N. Aiyudu, Lara W. Massie, Bindu V. Rusia, Charles Q. Li Published: 2025 ABSTRACT BACKGROUNDRadiation therapy is a common treatment for spinal metastases. However, its effects on extramedullary intrathecal structures are poorly understood. Arachnoid webs are rare structural abnormalities that can cause significant neurological symptoms due to spinal cord compression. While radiation-induced myelopathy is a rare known complication of radiation therapy, the potential relationship between radiation treatment and the formation or exacerbation of arachnoid webs has not been previously reported.OBSERVATIONSThe authors present the case of a 64-year-old female with breast cancer and spinal osseous metastases who underwent palliative radiation therapy. Six months after radiation therapy, she developed progressive myelopathy refractory to conservative treatments. Imaging revealed dorsal cord indentation and edema with findings suggestive of a compressive arachnoid web. Surgical intervention confirmed an extensive complex arachnoid web spanning T5–8. Fenestration of the web resulted in immediate intraoperative improvement in somatosensory evoked potentials and significant postoperative neurological recovery over 8 months.LESSONSThis case highlights the importance of considering structural abnormalities, such as arachnoid webs, in patients with progressive myelopathy following spinal radiation therapy, even when doses are within safe limits. Myelography may be helpful for characterizing intrathecal changes in this context. Further research is needed to explore the relationship between radiation therapy and arachnoid pathology. https://thejns.org/doi/10.3171/CASE25733 Radiation therapy is a common treatment for spinal metastases. Radiation-induced myelopathy is a rare, but potentially devastating complication of spinal cord irradiation resulting from damage to the white matter of the spinal cord due to vascular injury, demyelination, and/or alternations to the spinal cord microenvironment.1–6 The incidence of radiation-induced myelopathy is 0.2% when the radiation dose to the spinal cord remains under the recommended tolerance of 50 Gy in increments of 1.8–2 Gy per fraction.7 The risk of radiation myelopathy at palliative doses of radiation therapy of 8 to 30 Gy is exceedingly low. Radiation myelopathy typically presents in two forms: early delayed and late delayed. The early-delayed form occurs within 6 months after radiation therapy and is often transient and self-limited. The late-delayed form presents months to years after treatment and can lead to progressive and irreversible neurological deficits.4,5,8 MRI findings in radiation myelopathy include T2 hyperintensity, cord expansion, and variable enhancement patterns.2 While the effects of radiation on the spinal cord itself are well documented, the understanding of radiation’s effects to the surrounding structures, such as the arachnoid membrane, is limited. Arachnoid webs and cysts are rare structural abnormalities that can cause significant neurological symptoms secondary to spinal cord compression. There are several proposed mechanisms for the formation of arachnoid webs, including traumatic, infectious, postoperative, and congenital etiologies.9 In contrast, arachnoid cysts are thought to form from irregular CSF flow during embryonic development, where abnormal CSF pulse pressure may lead to trapped fluid when meninges close improperly.10 To date, there are no published articles directly linking prior spinal radiation therapy to the formation or alteration of arachnoid webs or cysts. Theoretically, radiation-induced inflammation and fibrosis of the arachnoid membrane could lead to adhesions and trabeculations that alter CSF dynamics, potentially contributing to the formation of arachnoid webs. The vascular changes and altered permeability of the blood–spinal cord barrier associated with radiation exposure could also play a role in modifying the arachnoid environment.2,4–6 In this paper, we present a unique case of a patient who developed a compressive complex multiloculated arachnoid web (a further description is in the Illustrative Case section below) following palliative radiation therapy for spinal metastases. This case highlights the importance of exploring alternative etiologies for myelopathy symptoms in an irradiated distribution, particularly when radiation dosage to the spinal cord is within accepted tolerance. Illustrative Case A 64-year-old female was initially diagnosed with right breast invasive ductal carcinoma in January 2022 and subsequently developed spinal osseous metastases in the T6 and T7 vertebrae (Figs. 1A and 2A). Systemic treatment for this patient’s breast cancer included TCHP (docetaxel, carboplatin, trastuzumab, and pertuzumab) initiated in June 2022, followed by maintenance therapy with letrozole, trastuzumab/pertuzumab, and denosumab. She underwent palliative external beam radiation therapy for bony metastases from T5 to T8, which consisted of 3000 cGy given over 10 fractions in January 2023. No concurrent chemotherapy was delivered at the time of radiation therapy. FIG. 1.Sagittal T2-weighted MRI sequences showing T6 and T7 osseous metastases and the extent of cord edema over time. A: Image obtained in March 2022 showing spinal canal narrowing with no cord edema. B: Image obtained in October 2023 showing dorsal cord indentation (arrow) with new cord edema spanning T3–7. C: Image obtained in December 2023 showing interval decrease in cord edema, likely secondary to recent steroid course. D: Image obtained in March 2025 (8 months postoperatively) showing interval resolution of cord expansion with minimal persistent T2 hyperintensity and new volume loss consistent with myelomalacia. FIG. 2.Sagittal T1-weighted fat-suppressed contrast-enhanced MRI sequences showing extent of cord enhancement over time. A: Image obtained in March 2022 showing osseous metastases in the T6 and T7 vertebrae with no cord enhancement. B: Image obtained in October 2023 showing new cord enhancement at the T6 level (arrow). C: Image obtained in December 2023 showing interval increase in cord enhancement. D: Image obtained in March 2025 (8 months postoperatively) showing persistent but decreased cord enhancement. Sagittal T2-weighted MRI sequences showing T6 and T7 osseous metastases and the extent of cord edema over time. A: Image obtained in March 2022 showing spinal canal narrowing with no cord edema. B: Image obtained in October 2023 showing dorsal cord indentation (arrow) with new cord edema spanning T3–7. C: Image obtained in December 2023 showing interval decrease in cord edema, likely secondary to recent steroid course. D: Image obtained in March 2025 (8 months postoperatively) showing interval resolution of cord expansion with minimal persistent T2 hyperintensity and new volume loss consistent with myelomalacia. Sagittal T1-weighted fat-suppressed contrast-enhanced MRI sequences showing extent of cord enhancement over time. A: Image obtained in March 2022 showing osseous metastases in the T6 and T7 vertebrae with no cord enhancement. B: Image obtained in October 2023 showing new cord enhancement at the T6 level (arrow). C: Image obtained in December 2023 showing interval increase in cord enhancement. D: Image obtained in March 2025 (8 months postoperatively) showing persistent but decreased cord enhancement. Approximately 6 months following her first radiation treatment (July 2023), the patient developed progressive myelopathy. Specifically, her symptoms included sensory changes below the T7 dermatome affecting bilateral lower extremities with burning/stinging paresthesias, saddle anesthesia, proprioception deficits, and painful spasms, all of which were refractory to conservative management. Thoracic spine MRI performed in October 2023 revealed no change in known osseous metastatic lesions, but there was new dorsal cord enhancement at the T6 level and significant cord edema spanning from T3 to T7 (Figs. 1B and 2B). The differential diagnosis at that time included delayed radiation myelopathy versus new intramedullary metastatic disease. An interdisciplinary neurological tumor board review concluded that the likelihood of intramedullary metastatic disease was extremely low. The spinal cord imaging findings on MRI were at the exact levels of the radiation field. However, radiation myelopathy was felt to be also highly unlikely in this patient, given the relatively short length of cord irradiation, no use of concurrent chemotherapy, and that the prescribed radiation dose of 3000 cGy in 10 fractions was well below the recommended tolerance of 4500–5000 cGy. Given that another etiology could not be identified, the patient was treated with a long course of high-dose steroids for presumed radiation-induced myelopathy. Her symptoms failed to improve with steroids; therefore, bevacizumab was then initiated as second-line therapy for radiation-induced myelopathy, which also did not improve symptoms. A follow-up thoracic spine MRI study on December 11, 2023, revealed an interval increase in cord enhancement but a decrease in cord edema. The improvement of edema was attributed to her recent steroid course. This MRI study also raised suspicion for an intrathecal structural abnormality at the T7 level, specifically, a focal indentation of the dorsal cord with possible ventral CSF effacement (Figs. 1C and 2C). Retrospective imaging review showed possible similar dorsal cord contour abnormality in March 2022 (prior to irradiation), although it was less pronounced at that time (Fig. 1A). The constellation of MRI findings was concerning for ventral cord herniation related to the presence of previously abutting vertebral body metastasis. A compressive dorsal arachnoid web or cyst was also a consideration, although considered less likely due to the absence of preradiation cord signal abnormality. A CT myelography study was performed on December 15, 2023, to evaluate for ventral cord herniation versus dorsal compression. The CT myelogram examination confirmed dorsal cord indentation at the inferior T7 level and ventral cord deviation, without ventral CSF effacement to suggest cord herniation or adhesion to the ventral thecal sac (Fig. 3). These findings were most consistent with compressive dorsal arachnoid web and associated venous congestion accounting for rostral cord edema and enhancement. FIG. 3.CT myelograms obtained in December 2023 showing ventral cord compression and dorsal cord indentation without complete ventral CSF effacement, most consistent with a compressive dorsal arachnoid web at the inferior T7 level. A and B: Sagittal (A) and axial (A) myelograms. The arrow indicates the dorsal cord deformity. C:Magnified sagittal image with drawn curve approximating the shape of the complex arachnoid web with a blind-ending pouch at T7 and an interspersed arachnoid band. CT myelograms obtained in December 2023 showing ventral cord compression and dorsal cord indentation without complete ventral CSF effacement, most consistent with a compressive dorsal arachnoid web at the inferior T7 level. A and B: Sagittal (A) and axial (A) myelograms. The arrow indicates the dorsal cord deformity. C:Magnified sagittal image with drawn curve approximating the shape of the complex arachnoid web with a blind-ending pouch at T7 and an interspersed arachnoid band. Given the progressive neurological decline, concerning imaging, and lack of improvement with multiple medical therapies, the patient underwent a T6–8 laminectomy and intrathecal exploration on August 15, 2024. Intraoperatively, a multiloculated intradural pouch of CSF compressing the cord was immediately observed spanning from T5 through T8 and extending laterally around the cord. Specifically, the abnormal structure appeared to be thickened arachnoid mater with interspersed arachnoid bands that terminated as a blind-ending pouch at the T5 level (Figs. 3C and 4). The arachnoid bands/webs were fenestrated until no inhibition to CSF flow was noted. Complete fenestration was confirmed with ultrasound. Intraoperative neurophysiological monitoring showed immediate improvement in somatosensory evoked potentials. FIG. 4.A: Intraoperative ultrasound image in the transverse plane showing open dural flaps (arrows) with complex arachnoid web and interspersed arachnoid bands (arrowheads) and the cord (asterisk). B: Intraoperative photograph showing thickened arachnoid web with arachnoid bands (arrows) corresponding with the intraoperative ultrasound photograph. A: Intraoperative ultrasound image in the transverse plane showing open dural flaps (arrows) with complex arachnoid web and interspersed arachnoid bands (arrowheads) and the cord (asterisk). B: Intraoperative photograph showing thickened arachnoid web with arachnoid bands (arrows) corresponding with the intraoperative ultrasound photograph. Postoperatively, the patient reported immediate improvement in lower extremity motor function and sensory symptoms. She demonstrated consistent improvement in ambulation, urinary incontinence, and lower extremity paresthesias, which continued to improve over the following several months. At her 8-month postoperative visit, the patient reported continued improvement in motor strength and balance with mild persistent weakness and paresthesias in bilateral lower extremities. The most recent thoracic MRI study, performed in March 2025, revealed decreased cord enhancement and resolution of expansion with minimal residual T2 hyperintensity and new volume loss, suggestive of persistent myelomalacia and injury (Figs. 1D and 2D). Informed Consent The necessary informed consent was obtained in this study. Discussion Observations While the clinical presentation and imaging findings in our case were initially suggestive of radiation-induced myelopathy, an important consideration was that the patient received a palliative radiation dose of 3000 cGy in 10 fractions, which is significantly lower than the expected threshold for myelopathy. The incidence of radiation-induced myelopathy is 0.2% when the radiation dose to the spinal cord remains under the recommended tolerance of 50 Gy in increments of 1.8–2 Gy per fraction. The risk of myelopathy increases exponentially at doses above this tolerance, with an estimated myelopathy risk of approximately 5% at 5400–6100 cGy and 50% at 6800–7300 cGy.7,11 In the absence of significant improvement with steroids, bevacizumab was attempted. The patient tolerated one cycle of bevacizumab and requested to discontinue due to reported worsening symptoms. While fatigue is a known adverse effect of bevacizumab, there have been no reports of worsening myelopathy as a side effect in the literature.12 It is unclear whether the subjective worsening of myelopathy was a result of extreme fatigue from the bevacizumab treatment or if the myelopathy was aggravated by another factor at that time. The ineffective medical management followed by immediate clinical improvements after surgical intervention confirmed the structural etiology of the patient’s symptoms and deficits. The continued neurological improvement over 8 months postsurgery as well as her most recent MRI findings further support this conclusion. To our knowledge, the development or exacerbation of arachnoid webs following radiation therapy, as seen in our case, has not been previously reported in the literature. While the exact mechanism remains unclear, we hypothesize that radiation-induced changes to the spinal cord and surrounding tissues likely contributed to the formation or alteration of the complex multiloculated arachnoid web, given that radiation therapy is known to cause fibrosis, vascular damage, and alter the permeability of the blood–spinal cord barrier.2,4–6 Lessons This case highlights the complexities involved in the diagnosis and management of myelopathy in patients with a history of spinal radiation therapy. It underscores the importance of considering radiation-induced myelopathy, intramedullary metastasis, and intrathecal structural lesions, such as arachnoid webs, as various potential etiologies of progressive myelopathy. While limited in scope to only one example of an arachnoid anomaly exacerbated by radiation therapy, this case raises important questions about the long-term effects of radiation on spinal canal structures beyond the cord itself. It suggests that clinicians should maintain an index of suspicion for structural abnormalities in patients with a history of spinal radiation therapy who present with progressive myelopathy, even when initial imaging does clearly indicate an underlying etiology and radiation doses are within conventionally accepted safe limits. When there is reasonable cause for suspicion, workup should include myelography for evaluation of intrathecal changes that could result in impediments in CSF flow, which are potentially undetectable on MRI. Further research is needed to elucidate the potential relationship between radiation therapy and the development or exacerbation of abnormalities in the arachnoid environment. Prospective studies examining the long-term effects of radiation on intrathecal structures could provide valuable insights into this possible association and inform future treatment strategies. Disclosures The authors report no conflict of interest concerning the materials or methods used in this study or the findings specified in this paper. Author Contributions Conception and design: all authors. Acquisition of data: Spencer, Aiyudu, Massie. Analysis and interpretation of data: all authors. Drafting the article: Spencer, Rusia. Critically revising the article: all authors. Reviewed submitted version of manuscript: Spencer, Massie, Rusia, Li. Approved the final version of the manuscript on behalf of all authors: Spencer, Statistical analysis: Spencer. Administrative/technical/material support: Spencer, Massie. Study supervision: Li. Correspondence Raven D. Spencer: Allegheny Health Network, Pittsburgh, PA. raven.spencer@ahn.org.